Ask AI
ProCE Banner Activity

Risposte alle domande chiave sul trattamento ottimale per i pazienti con leucemia linfatica cronica recidivata/refrattaria

Clinical Thought

In questa attività, gli esperti affronteranno le questioni chiave nella cura dei pazienti con leucemia linfatica cronica (CLL) recidivata/refrattaria (R/R), in base alla discussione tenutasi in un precedente webinar dal vivo. Queste risposte serviranno a fornire informazioni concrete e applicabili, che gli operatori sanitari coinvolti potranno utilizzare nella loro attività clinica.

Released: December 23, 2024

Expiration: December 22, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Faculty Disclosure

Primary Author

Othman Al-Sawaf, MD

Department of Hematology and Oncology
University Hospital of Cologne
Cologne, Germany

Othman Al-Sawaf, MD: consultant/advisor/speaker: AbbVie, Adaptive, AstraZeneca, BeiGene, Gilead, Janssen, Lilly, Roche; researcher: AbbVie, BeiGene, Janssen, Roche.

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh T. Awan, MD, MS, MBA: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, ADCT Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Dava Oncology, Genmab, Incyte, Kite, Loxo Oncology; researcher: AbbVie/Pharmacyclics.

Alessandra Tedeschi, MD

Medical Doctor
Department of Hematology
Niguarda Cancer Center Milano
Milano, Italy

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Johnson & Johnson.